Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856303) titled 'SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Fudan University

Condition: HER2-positive Breast Cancer Early Breast Cancer (EBC)

Intervention: Drug: SHR-A1811 Drug: Trastuzumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 1, 2026

Target Sample Size: 358

Countries of Recruitment: China

To kno...